Mersana Therapeutics, Inc.

NASDAQ:MRSN

2.12 (USD) • At close September 18, 2024
Bedrijfsnaam Mersana Therapeutics, Inc.
Symbool MRSN
Munteenheid USD
Prijs 2.12
Beurswaarde 260,071,000
Dividendpercentage 0%
52-weken bereik 1.065 - 6.28
Industrie Biotechnology
Sector Healthcare
CEO Dr. Martin H. Huber Jr., M.D.
Website https://www.mersana.com

An error occurred while fetching data.

Over Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660,

Vergelijkbare Aandelen

Aerovate Therapeutics, Inc. logo

Aerovate Therapeutics, Inc.

AVTE

1.91 USD

Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc.

CMPX

1.63 USD

Utah Medical Products, Inc. logo

Utah Medical Products, Inc.

UTMD

67.22 USD

Kezar Life Sciences, Inc. logo

Kezar Life Sciences, Inc.

KZR

0.576 USD

InterCure Ltd. logo

InterCure Ltd.

INCR

1.06 USD

Icosavax, Inc. logo

Icosavax, Inc.

ICVX

15.31 USD

Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc.

ANIK

25.47 USD

EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc.

EYPT

8.91 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)